Becton, Dickinson and Company $BDX Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 23.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 103,737 shares of the medical instruments supplier’s stock after selling 31,013 shares during the quarter. Corient Private Wealth LLC’s holdings in Becton, Dickinson and Company were worth $17,869,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Saudi Central Bank bought a new position in shares of Becton, Dickinson and Company during the first quarter worth about $26,000. Bell Investment Advisors Inc raised its stake in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 128 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA bought a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $31,000. Bank of Jackson Hole Trust grew its position in shares of Becton, Dickinson and Company by 85.6% in the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after acquiring an additional 95 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $36,000. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total transaction of $123,302.87. Following the completion of the sale, the executive vice president directly owned 13,105 shares of the company’s stock, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 1,036 shares of company stock worth $197,225. Company insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on BDX shares. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Jefferies Financial Group boosted their price objective on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Argus raised their target price on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Finally, Morgan Stanley upped their target price on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and a consensus price target of $205.64.

Becton, Dickinson and Company Trading Down 0.5%

Becton, Dickinson and Company stock opened at $195.46 on Thursday. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $55.79 billion, a price-to-earnings ratio of 33.53, a PEG ratio of 1.81 and a beta of 0.25. The firm has a 50-day moving average price of $189.18 and a two-hundred day moving average price of $185.09.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.32 billion for the quarter. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.1%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date of this dividend is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.